ASX:KZA

Email Alerts for:
ASX:KZA

Sector Watch: Healthcare - M&A fever on the cards?

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower

11 May 2022 - Wall St closed mixed lifted by information tech and M&A news in the biotech sector as dip buyers emerge ahead of the next CPI print. Shanghai stocks bucked the trend …

Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug

03 Dec 2021 - Kazia Therapeutics (ASX:KZA) has announced positive results from its Phase II study into the treatment of glioblastoma with paxalisib.

Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial

09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.

Kazia Therapeutics (ASX:KZA) glioblastoma Phase II trial results

27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE …

Kazia Therapeutics (ASX:KZA) clinical trial update presentation, FNN Investor Event, October 2018, Sydney

22 Oct 2018 - Kazia Therapeutics Limited (ASX:KZA) CEO and Executive Director Dr James Garner provides an update on the company's two clinical stage drug development candidates for…

Kazia Therapeutics (ASX:KZA) clinical trial update

22 Oct 2018 - Kazia Therapeutics Limited (ASX:KZA) CEO and Executive Director Dr James Garner provides an update on the company's two clinical stage drug development candidates for…